EP2983634A1 - System und verfahren zur behandlung von hufrehe - Google Patents
System und verfahren zur behandlung von hufreheInfo
- Publication number
- EP2983634A1 EP2983634A1 EP13881978.4A EP13881978A EP2983634A1 EP 2983634 A1 EP2983634 A1 EP 2983634A1 EP 13881978 A EP13881978 A EP 13881978A EP 2983634 A1 EP2983634 A1 EP 2983634A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- animal
- inflatable chambers
- distal
- leg
- wrap member
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- 238000011282 treatment Methods 0.000 title claims abstract description 39
- 241001465754 Metazoa Species 0.000 claims abstract description 62
- 239000003814 drug Substances 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 238000002483 medication Methods 0.000 claims abstract description 10
- 230000004087 circulation Effects 0.000 claims abstract description 8
- 210000000003 hoof Anatomy 0.000 claims description 45
- 241000283073 Equus caballus Species 0.000 claims description 42
- 230000003252 repetitive effect Effects 0.000 claims description 29
- 230000000304 vasodilatating effect Effects 0.000 claims description 6
- 238000002691 topical anesthesia Methods 0.000 claims description 5
- 230000002250 progressing effect Effects 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 1
- 241000283086 Equidae Species 0.000 abstract description 7
- 235000004869 Tussilago farfara Nutrition 0.000 abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 230000006835 compression Effects 0.000 description 20
- 238000007906 compression Methods 0.000 description 20
- 208000002193 Pain Diseases 0.000 description 19
- 230000036407 pain Effects 0.000 description 19
- 210000002414 leg Anatomy 0.000 description 18
- 210000003414 extremity Anatomy 0.000 description 16
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 11
- 206010030113 Oedema Diseases 0.000 description 11
- 210000000988 bone and bone Anatomy 0.000 description 10
- 210000002435 tendon Anatomy 0.000 description 10
- 206010052428 Wound Diseases 0.000 description 9
- 230000006837 decompression Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 239000004744 fabric Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 5
- 201000002282 venous insufficiency Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 208000004210 Pressure Ulcer Diseases 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 206010011985 Decubitus ulcer Diseases 0.000 description 3
- 206010015548 Euthanasia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010025282 Lymphoedema Diseases 0.000 description 3
- 208000000491 Tendinopathy Diseases 0.000 description 3
- 206010043255 Tendonitis Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000002502 lymphedema Diseases 0.000 description 3
- 238000006213 oxygenation reaction Methods 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 201000004415 tendinitis Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 229910001369 Brass Inorganic materials 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000010951 brass Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 230000036555 skin type Effects 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009724 venous congestion Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229920000079 Memory foam Polymers 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 240000000377 Tussilago farfara Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047095 Vascular pain Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000008210 memory foam Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H9/00—Pneumatic or hydraulic massage
- A61H9/005—Pneumatic massage
- A61H9/0078—Pneumatic massage with intermittent or alternately inflated bladders or cuffs
- A61H9/0092—Cuffs therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D9/00—Bandages, poultices, compresses specially adapted to veterinary purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H9/00—Pneumatic or hydraulic massage
- A61H9/005—Pneumatic massage
- A61H9/0078—Pneumatic massage with intermittent or alternately inflated bladders or cuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/16—Physical interface with patient
- A61H2201/1602—Physical interface with patient kind of interface, e.g. head rest, knee support or lumbar support
- A61H2201/164—Feet or leg, e.g. pedal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/16—Physical interface with patient
- A61H2201/1602—Physical interface with patient kind of interface, e.g. head rest, knee support or lumbar support
- A61H2201/165—Wearable interfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5002—Means for controlling a set of similar massage devices acting in sequence at different locations on a patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5005—Control means thereof for controlling frequency distribution, modulation or interference of a driving signal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5023—Interfaces to the user
- A61H2201/5035—Several programs selectable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5023—Interfaces to the user
- A61H2201/5038—Interfaces to the user freely programmable by the user
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2203/00—Additional characteristics concerning the patient
- A61H2203/03—Additional characteristics concerning the patient especially adapted for animals
Definitions
- the present invention relates generally to a circulatory treatment system and method useful particularly in reducing the symptomatology and/or rehabilitation of a condition known as laminitis and other debilitating conditions in the leg of an equine or similarly structured animal.
- One of the inventors in this application is a physician, who is a plastic and reconstructive surgeon and a wound healing specialist practicing for more than twenty- five years. In his practice he has encountered, studied, and treated all wounds on every location of the human body. His experience confirms that, whatever the mechanism of action, surgical, traumatic, neo-plastic, arterial disease, venous stasis, lymphatic, pressure, infectious, caustic, thermal, hypothermal, infarction, or (strangulation), every and all wounds are the direct result of the disruption of the circulatory system.
- Laminitis is defined as the debilitating persistent and chronic condition of horses' hooves, which occurs when a critical mass of the interwoven complexes of connective tissue and blood vessels which hold the distal phalanx, P3, (coffin bone), to the inner surface of the keratinized hoof, fail to function. This is the result of a number of systemic and physiological causes.
- the attachments separate, become “devascularized” and detach from the hoof's inner wall.
- the strong pull of the deep flexor tendon on the coffin bone and the combination of the weakened attachments causes the bone to rotate downward creating severe pain, edema, venous congestion and lymphedema and significant debilitation. When left unchecked, this condition results in "founder” an old term for exposure of the coffin bone, through the sole of the hoof. This most commonly renders the animal unable to survive and usually results in euthanasia.
- the external compression devices currently on the market decrease the congestion, drive the third space proteinaceous material and lymphatic drainage back into the venous system, relieving the skin of pressure, and improving the condition of wounds. All of these external devices mimic the return flow of the venous system as well as decompress and mobilize the third space edema.
- the decompression of the lymphatic system thus reduces the overall pressure on the arterial system. This is all achieved by improving the gradient between the arterials and the venules, thus improving the overall extremity flow, oxygenation and wound healing. Oxygenation and arterial flow is necessary for all wounds to heal. Venous stasis in tissue can destroy an extremity.
- a long recognized modality of venous decompression used for centuries is the application of leeches, which allow for continued arterial flow increasing oxygenation.
- the laminitis literature implicates a multitude of factors causing this condition: overfeeding, carbohydrate overload, stress, genetics, insulin resistance, injury, and Cushing's syndrome.
- the cycle as described is pain, inflammation, venous stasis, more inflammation and more pain.
- the secondary effects of the tendonitis render the animal so incapacitated as to be "paralyzed”.
- the cycle must be broken either by stopping the edema (stasis), decongesting the arterial flow, or controlling the pain.
- leg including hoof enveloping garment; chambers equipped with D-rings on Velcro® brand fasteners or similar supplier;
- apparatus lining with fleece or sheep's skin, removable and washable so as not to transfer body fluids associated with cross contamination, for,
- the NormaTec device or similar supplier is basically a legging. It is a unitary circumferential device. The patient steps into or pulls the legging into or over a secondary garment - a cotton stocking extending from the lower extremity of the foot upward to the thigh.
- the legging usually consists of four to five pneumatic chambers depending on the size of the patient.
- the apparatus will necessitate being applied as a wrap rather than a contiguous pants-like legging (in humans it must be applied in the recumbent position which is not the case with the equine who stands from the moment of birth).
- Lifting the leg will not be an option for two reasons:
- the condition of laminitis will not accommodate the lifting of one front leg because of the associated pain i.e. the horse's stance is now a tripod.
- the literature surrounding laminitis regularly refers to the horse's feet being "nailed to the ground”.
- the boot In the event of an emergency, the boot will need to be removed rapidly, i.e. if the animal goes down or needs other emergency treatment, he will entangle himself and needs to be disengaged rapidly and easily.
- the wrap member will need a fleece or sheep skin type removable lining for the comfort and therapeutic administration of the appropriate pressures and to minimize the contact and heat generated by frictional forces.
- the attachments typically will have to include D- Ring, Velcro® brand fasteners so as to draw upon themselves when inflated, and to avoid opening during the inflation phase.
- the attachments alternate, left to right, from top to bottom.
- the tubing will be of a larger bore:
- the NormaTec device as it exists, has a long inflation time, and a long deflation time (both upwards of three minutes). This is because existing NormaTec tubing, which transfers the air pressure, has very small caliber diameter openings - less than one quarter inch(6.35mm). This restricts the inward and outward flow of the air, prolonging the treatment.
- the interposed compressor or air chamber will ensure 15 seconds or less as a maximum inflation time and a compression(Pn hereinafter) or decompression(PL hereinafter) interval of less than 15 to 30 seconds.
- This in conjunction with the larger tubing, will also allow for the more rapid inflow and outflow, shortening the overall duration of the treatment.
- This more rapid interval of compression and decompression is necessary in an animal of prey, which is genetically geared to "fright or flight", and will allow for a more rapid accommodation to the device. The animal will tolerate rapid touching and decompression but would not tolerate grabbing and holding.
- the NormaTec PCD device or similar device requires either stopping the air flow or interrupting the connection tubing in an emergency situation for decompression and removal of the garment. Because of the narrow tubing, decompression is very slow. The larger the garment, the more volume and the more difficult to deflate rapidly. This coupled with the small diameter of the tubing will create a problem for a horse. A fully inflated cycling garment will not allow the joints to flex since the animal is in a standing position. If the horse were to collapse without the garment deflating quickly enough, a fracture, dislocation or other permanent injuries could easily occur. A quick release valve, with a wide port, will be used to assist in the rapid decompression and quick removal of the compression wrap member, when necessary.
- a method of treatment for the treatment principally of circulation problems in hoofed animals such as a horse.
- the invention includes the provisioning of a wrap member, having a predetermined length and a plurality of inflatable chambers, including a most distal one and a most proximal one, positioned at respective intervals along the length of the wrap member.
- the most distal one of the plurality of inflatable chambers is adapted to engage a compressible portion of the leg of the animal exposed within the hoofed area.
- the wrap member further includes the means to releasably secure the wrap member to the leg of the animal; [0031]
- the methodology further requires the provisioning of a controllable pressure source which is connected to each of the inflatable chambers.
- the methodology calls for manipulating the wrap member using the means for releasably securing the wrap member, to position and secure the wrap member about the leg of the horse.
- the most distal one of the chambers engages the compressible portion of the leg of the animal exposed within the hoofed area.
- the most proximal one of the chambers engages a higher portion of the leg of the animal in an area predetermined by the length of the wrap member;
- the controllable pressure source is adapted to provide a plurality of repetitive cycles. Each one of the repetitive cycles comprises a first predetermined number of successive time intervals.
- the controllable pressure source is further adapted to provide during each time interval during the repetitive cycles, either a predetermined pressure of a higher magnitude, P H , or of a lower magnitude, P L , to a respective one of the plurality of inflatable chambers in accordance with a predetermined wave pattern, wherein the predetermined wave pattern requires that during each time interval of the one of the repetitive cycles, at least two immediately adjacent inflatable chambers are at P H pressure and at least one of the inflatable chambers is at P L pressure.
- the at least two immediately adjacent inflatable chambers at P H pressure over the time of each the repetitive cycle progress from the most distal inflatable chamber and the next most distal one to the most proximal one and the next most proximal one.
- the method of treatment further calls for the controllable pressure source to provide at least one ramp-up cycle extending over a second number of successive time intervals prior to the beginning of the repetitive cycles.
- the ramp-up cycle comprises a varying combination of the inflatable chambers inflated at P H and P L in accordance with a predetermined sequence based on the predetermined wave pattern.
- the method of treatment still further calls for the controllable pressure source to provide at least one fill cycle prior to providing the at least one ramp-up cycle.
- each of the inflatable chambers is filled at a pressure less than Pn and typically, P L .
- the method of treatment still further calls for the disposition of the most distal one of the plurality of inflatable chambers within a boot which is releasably secured to the hoof of the animal.
- the boot is adapted to assist in the engagement of the most distal one of the inflatable chambers with the compressible portion of the leg of the animal.
- the method of treatment still further calls for the disposition of an inner sole pad between an upper surface of the most distal one and the compressible portion of the leg of the animal exposed within the hoofed area.
- the pad facilitates the interaction between the bladder and the exposed area.
- the method of treatment identifies that the inner sole pad is adaptable to be impregnated with a variety of medications including vasodilatory and topical anesthesia medications; as well as adaptable to be a facilitator with an electronically charged medicament delivery system.
- FIG. 1 is a perspective view of the compression wrap member portion of this invention prior to installing onto the leg of a horse;
- Fig. 2 is an exploded perspective view of the compression wrap member portion of this invention showing the inner cover material above the series of bladders in place upon the outer material prior to final assembly;
- Fig. 2A is an exploded perspective view of a single bladder shown above the outer material
- Fig. 3 is a bottom plan view of a bladder as taken along view line 3-3 of Fig. 2A;
- Fig. 4 is a cross-sectional view as taken along section line 4-4 of Fig. 3;
- Fig. 5 is a partial transverse cross-sectional view of a horse's hoof.
- Fig. 5 A is a bottom plan view of a horse hoof as taken along view line 5A-5A of Fig. 1;
- FIG. 6 is a perspective view of a front, left horse leg with the compression wrap member portion of this invention in place;
- Fig. 6A is a perspective view of a strap with D-ring used to secure the wrap member to the animal's leg;
- Fig. 6B is a perspective view of a strap with a double D-ring used to secure the wrap member to the animal's leg;
- Fig. 7 is a partial, transverse cross-sectional view of the compression wrap member portion of this invention as shown in place in Fig. 6, including, principally, the segment that covers the hoof;
- Fig. 8 is a bottom plan view similar to Fig. 5A wherein the lower bladder and silicon pad of the present invention are in place;
- Figs. 9 and 9A through 9J are respective schematic views depicting the various stages of sequential pressurization of the bladder members in implementing the methodology of this invention for different numbers of chambers and pressure wave patterns.
- Fig. 10 is partial perspective and schematic view of the controllable pressure source portion of the invention including the connection to the bladder portion of the wrap member in place on the animal.
- a compression wrap member 20 portion of the system of the present invention is shown prior to installation on the animal. It includes a garment section 22 with a series of bladders, not readily seen in this figure, interposed between the layers of the garment section.
- the wrap member 20 includes a hoof covering segment 24 as well as means 26 for releasably securing the wrap member 20 to the horse's limb.
- These typically comprise hook and loop, VELCRO or similar supplier straps available from "Seattle Fabrics", of Seattle, Washington or similar supplier and include respective D-rings again not shown in this view, so as to draw upon themselves when inflated, thus maintaining the chamber demarcation and to avoid opening during the inflation phase.
- the hook and loop portions alternate in their placement, on the left or right of the closure, from the top to the bottom of the wrap member.
- a plurality of compressed air supply tubes 28 are secured to the compression wrap member in a manner to be discussed hereinafter.
- the plurality of tubes further connects to a fluid supply, typically a tank of compressed air, not shown in this view.
- the tubing is of a larger bore sufficient to initiate the flow more quickly and to assure the deflation cycle occurs more rapidly.
- the tubing inner diameter would be on the order of 0.5 inches(12.7mm).
- the tubing can be reinforced in a known manner to ensure that it does not collapse during use.
- the tubing for the NormaTec device has relatively small diameter openings which prolong the treatment cycle. For one chamber the cycle time for the NormaTec device is greater than 30 seconds. For a five chamber device the overall cycle time for the NormaTec device from the distal to proximal chambers would be a minimum of 150 seconds. Our invention is designed to greatly reduce these times.
- Means for securing the two layers of garment section 22 together are depicted at the perimeter 30. This can be implemented using the heat sealing characteristics of the materials comprising the two layers as noted below or by using radio frequency(RF) techniques..
- the typical length anticipated, 32 is on the order of 30 to 35 inches(76 to 89 cm) or tailored (custom) for a specific animal.
- the width 34 it is anticipated, would be on the order of 28 inches(71cm).
- the wrap member may be configured as tapered from a larger width at its proximal end to a smaller width at the hoof or distal end.
- Garment section 22 includes top layer 36 and bottom layer 38.
- Each layer, 36 and 38, are made of heat sealable (or RF) pack cloth material (for example Gortex), available from "Seattle Fabrics” of Seattle, Washington or similar supplier.
- RF heat sealable pack cloth material
- a series of 5 bladders, non porous 40, 42, 44, 46, and 48 are depicted, spaced along the length of layer 38.
- the methodology of the invention allows for as few as three bladders. However, the practicalities of the device's application, especially with equines, warrant, no less than a four bladder configuration, and typically one with five bladders as depicted in Fig. 9.
- a higher number of individual bladders is possible as dictated by circumstances and the limitations of manufacture.
- a higher number of bladders may provide a degree of redundancy in case of an unknown bladder failure during use.
- the bladders overlap a respective, adjacent bladder. This overlap is approximately 1/3. So, bladder 42 overlaps bladder 40; bladder 44 overlaps bladder 42; bladder 46 overlaps bladder 44; and bladder 48 overlaps bladder 46.
- the topside surface of layer 36 as seen in Fig. 2 may include a method of fastening(lengthwise VELCRO brand hook and eye strips are shown) a removable and reusable lining 37 such as a soft KODEL, or similar market type, fleece or sheep skin lining (not shown). This top side surface will be immediately adjacent the horse's skin. Thus the softer lining will minimize the discomfort, absorb perspiration, and decrease friction of cycling associated with the wrap member in place.
- the bladders are made of heat, RF, or similar technology, sealable, Oxford nylon fabric also available from "Seattle Fabric” of Seattle, Washington or similar supplier.
- Figure 2A is a perspective view of a typical bladder, such as 48, disposed above bottom layer 38 of garment section 32.
- layer 38 is heat, RF, or similar technology sealable pack cloth material.
- VELCRO or similar supplier pads 50 and 52 a total of 10 for a 5 bladder configuration
- a VELCRO or similar supplier disc 54 a total of 5, again, for a 5 bladder configuration
- a hole 56 is formed in both the layer 38 and VELCRO or similar supplier disc 54 to provide access for a fitting disposed on the bladder and which will be discussed hereinafter.
- Figure 3 depicts the underside of a typical bladder as shown in Figure 2A.
- Each bladder is seen to include corresponding VELCRO or similar supplier pads 58 and 60 and VELCRO or similar supplier disc 62. These are positioned and complement the corresponding pads disposed on layer 38 and discussed above with respect to Figure 2A.
- FIG. 4 shows in section, the construction of a typical bladder such as 48.
- a bladder includes layer(s) 64 and 66 which, again, is heat sealable Oxford or similar market supplier material available from "Seattle Fabrics".
- the layers 64 and 66 are heat sealed along perimeter edge 68 to provide a sealed volume 69 interior to the inside surfaces of layers 64 and 66.
- a brass (or similarly stiff product) crescent-shaped backer plate 70 is disposed in the volume 69 and bonded to the underside surface 72 of layer 64.
- the complementing VELCRO or similar supplier disc 62 is likewise bonded to the outside surface 74 of layer 64.
- Secured to the backer plate 70 is a brass (or similarly stiff product) right angle bulkhead fitting which includes a barbed end 78.
- the barbed end 78 is secured to a corresponding tube of the grouping 28.
- each bladder may be further secured to layer 38 by heat tacking at different points, along the perimeter edge 68, to the layer 38. This will prevent the bladder from twisting inside the enclosure formed by layers 36 and 38.
- FIG. 5 shown in partial, transverse cross-sectional view is a horse's hoof.
- Relevant parts of the hoof for purposes of this description include the digital cushion area 80 which comprise a frog segment 82 and the bulbar area 84.
- the phalanx associated with the laminitis condition, the distal phalanx or P3, is identified by reference numeral 86.
- Secured to the under surface of the distal phalanx is the deep flexor tendon 88.
- Extensor tendon 90 is connected to the forward surface of P3.
- Covering the upper surface of the distal phalanx is an area known as the laminar corium 92.
- the corium consists of a dense matrix of tough, connective tissue containing blood vessels and nerves.
- the frog segment 82 is somewhat of a heart-shaped structure that extends forward across about two-thirds of the sole. At the back it merges with the heel and the bulbar area of the digital cushion. Of importance to the present invention is the fact that the frog acts like a pump to move the blood back to the heart - a great distance from the relatively thin leg to the main organ of the circulatory system.
- the frog is anatomically analogous to the human finger tip.
- the wall is anatomically analogous to the finger or toenail of a human.
- Fig. 6 shows the compression wrap member portion 20 of the invention in place on the horse's or animal's limb.
- the VELCRO or similar supplier straps 26 with D-rings allow for the draw down of the wrap in an alternating way.
- the strap on the chamber 103 immediately above the hoof is drawn to the left as viewed in Fig.6; while the immediately adjacent strap above is drawn to the right, and so forth up the leg.
- the straps 26 are generally positioned at the center of a respective chamber.
- the D-ring forces the VELCRO or similar supplier strap to draw upon itself when inflation occurs so as to preclude the release of the strap and thus the opening of the wrap member. (See Fig. 6A).
- VELCRO or similar supplier straps, or equivalent releasably securing means allows for the almost immediate removal of the wrap member from the horse's leg. This is important in that a horse is a fidgety animal and is disturbed at the smallest upset. The ability to unravel the wrap member relatively quickly assures that the horse does not become entangled in the compression wrap member and tubing which might create the possibility of further serious injury.
- Fig. 6B depicts another arrangement for releasably securing the straps 26.
- a double D ring is shown and the method of cinching the strap.
- the end of the strap can include a Velcro portion which engages a complementing portion to keep the end from flapping. This can be used instead of the single D-ring Velcro arrangement of Fig. 6A; or in addition to the Fig. 6 A arrangement if a finer adjustment in tying down a particular chamber(s) is needed, especially when the therapeutic cycling is underway.
- the inflatable bladders are within the garment which is in contact and surround completely the horse's or animal's limb.
- Tubing 28 is dressed along the length of the wrap member and is directed in a safe manner away from the horse to the pressure source and system control means (see Fig.10),
- the hoof covering segment 24 is also shown in place and its interrelationship or interaction with the hoof is better understood from viewing Figures 7 and 8.
- the wrap member is shown secured in place by the tightening down the respective VELCRO or similar supplier straps 26.
- Hoof covering segment 24 is similarly secured through its VELCRO or similar supplier connection 104.
- boot 24 serves multiple purposes.
- the de-lamination of the lamellae between the inner surface of the hoof wall and the digital phalanx results in the hoof starting to splay outward such that the sole becomes flatter.
- the wall integrity of the hoof is maintained and is protected against splaying while at the same time keeping the painful sole off of hard surfaces.
- the boot is made in a similar manner to the shoe worn by horses known as the "Sport Boot” by CAVALLO® or similar supplier.
- the soles of the boot 106 have a tread surface and include a rounded anterior front segment 108.
- the treads provide substantial traction for the animal.
- the sole treads can be constructed of recycled tires as a cost efficiency factor.
- the boot includes an upper leather portion 110 which can be lined with fleece or a sheep skin type lining; and includes a nylon cover to minimize dirt and stone abrasion.
- Bladder 40 includes a tongue-shaped segment 112 (see particularly Fig. 2).
- the tongue-shaped segment 112 is disposed in the boot and is of sufficient length to cover the sole and frog areas of the horse's hoof, as well as engage the bulbar portion of the digital cushion 80.
- This segment stimulates the horse's circulatory system in the hoof area in accordance with the principles of the invention.
- As part of the inflation/deflation cycle of the present invention see discussion for Fig. 9 below, it will assist the frog segment in pumping blood from the distal end of the limb to the proximal end.
- An inner sole pad 114 made of a strong density, non-memory foam or silicone pad is interposed between the upper surface of bladder segment 112 and the frog-sole area of the animal's hoof.
- the pad is slightly elevated (thicker) in its central posterior area.
- segment 112 When the bladder system is pressurized, segment 112 will urge the silicone pad upward against the resistance of the frog segment.
- the silicone gel will have enough give to deform laterally and, when released, enough memory to resume its normal shape.
- the boot with the inner sole pad 114 can remain in place on the hoof when the compression wrap member is removed.
- the upper margin of the boot will have 2 or 3 "V" shaped darts lined with heavy duty elastic attached to either side of the V cut and spanning the latter.
- This provides a simple mechanism for keeping the boot on the hoof in addition to the VELCRO straps or similar market supplier.
- the edge of the boot can be rolled and or padded to minimize irritation to the coronary band and other immediately adjacent segments of the horse's hoof.
- the boot portion of the invention will accomplish or assist in one or more of the following.
- the device will provide the appropriate ground protection and traction so that the animal, having difficulty walking because of the rotation of the coffin bone and the pain it causes with the ability to "round over”, will not stumble or fall.
- trans (hoof) cutaneous delivery of topical anesthesia to relieve the discomfort and minimize the side effects of long term therapy, which will be needed.
- This in conjunction with the electrical stimulation effect of the tens trans dermal unit will reduce pain and assist in revascularization as soon as possible. This will help to re-stabilize the scar formation to stop further rotation of bone.
- the efficiency of the boot will provide horse owners with a more rapid healing process, a decrease in the recuperation and down time and most importantly, the reduction of pain for the animal and overall remission of the disease more quickly. Expanding its usefulness we can include stone bruises, thrush, vascular and foot pain in general.
- a controllable pressure source includes a pump 116 connected through an appropriately sized expansion tank 118 to a known form of a valve control block 120.
- the expansion tank maintains a suitably stable pressure head at the input to the valve control block so that the constant pressures, P H and P L can be developed and maintained throughout the therapeutic procedure.
- the valve control block 120 includes a suitable valve package and pressure reducers so as to inflate, deflate and otherwise control the flow and magnitude of the pressurized fluid to and from the respective bladders positioned in the compression wrap member.
- a suitably programmed CPU 122 is accessed and directed, as needed, by a user through a suitable input device 124, such as a keyboard. The CPU will direct the valve control block to supply appropriate pressure levels for given time intervals, also controlled in number and length by the controllable pressure source, as may be guided by a therapy plan, such as reflected by the various Figures, 9 through 9J.
- the number of bladders for purposes of this embodiment are five; and, again, they can vary from a minimum of three to a higher number as dictated by the practicalities of the application and the needs of a particular circumstance. The higher the number, the more effective the control and overall efficacy.
- the other variables that change will be the number of fill intervals which are directly related to the number of chambers, i.e. number of chambers equal the number of fill intervals; and the number of ramp-up intervals where the number of intervals will equal the number of chambers minus the number of P L in a complete wave, minus one
- each chamber is filled with a low pressure P L . This is typically 0 to 15 mm Hg.
- P L a low pressure
- Chamber number 1 is maintained at P L and the valve to chamber 2 is opened and it, too, reaches P L
- Each of the remaining chambers over the course of time intervals 1 through 5, are pressurized at the low pressure level, P L
- the fill cycle is complete.
- the number of time intervals to reach the "fill" point is equal to the number of chambers.
- the ramp-up cycle is initiated. The purpose of the ramp-up cycle is to transition the system from the "quiet" fill cycle to the dynamic, repetitive cycle.
- the number of time intervals required to "ramp-up" to the repetitive, therapeutic stage are established by the number of chambers and the characteristics of the pressure wave that is to be established for the repetitive cycle (a "pressure wave” is defined as a single combination or set of adjacent P H pressurized chambers, taken as a single unit for this determination, and the number of adjacent P L inflated chambers, counted individually, again when used to determine the length of the ramp-up cycle).
- the number of time intervals to achieve the ramp-up cycle is the sum of the number of chambers at P L in the wave pattern, plus l(for the P H set) subtracted from the total number of chambers for a given wrap garment.
- the pressure wave in Fig. 9 for a five chamber device comprises two adjacent chambers pressurized at P H (counts as one) and one chamber pressurized at P L . According to the above this results in a ramp-up cycle of three (five minus (one plus one)) time intervals before the system enters the repetitive cycle phase.
- pressure to chamber 1 is now increased to a higher, therapeutic pressure P H.
- P H is in the range of 0 to 200 mm Hg, and within a preferred range of 10 to 60 mm Hg, but always in excess of P L. Chambers 2 through 5 remain at the low pressure status.
- chamber number 2 is now inflated with the higher pressure.
- chamber 1 is maintained at the higher pressure so as to eliminate back flow possibilities from the physical area of the horse's leg engaged by bladder number 2 into the area covered by bladder number 1, the hoof area.
- the controlled pressure source continues to direct the pressurization of chamber number 2 at P H , and, although not readily apparent from the drawings, retains pressurization of chamber number 1 at PH until pressurization of number 3 is achieved, whereupon pressurization of chamber number 1 is reduced to P L .
- the system as adapted does not permit back flow from a higher number chamber to a lower numbered one, i.e a more distal one.
- the results achieved by the apparatus and method of the present invention are significantly advantageous.
- the programmed controller 120 will return the wrap member, and particularly the bladders, to the interval and pressure just prior to the ramp-up cycle. In the embodiment illustrated in Fig. 9, this would be time interval number 5, where all the chambers are in their low pressure status, P L (of course, if the wrap member is to be removed, the valve control block 120 can be directed to release all pressurized fluid to the respective chambers).
- the controller would direct the restart of the ramp-up cycle, in a manner similar to what occurs at time interval number 6.
- the pressure levels and length of time intervals (5 sec to 30 sec preferred for the therapeutic, repetitive range) are largely a variable based in part on the condition of the animal.
- the approach described allows the animal to get acclimated to the device by gradually increasing pressure and/or adjusting the time interval, dependent on condition. All are programmable in the controller by the CPU as inputted to by a user. It is known how to vary these pressure levels and time intervals in related technology so as to effect the ramp up and repetitive cycles as depicted in Figure 9.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Rehabilitation Therapy (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Percussion Or Vibration Massage (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2013/036179 WO2014168624A1 (en) | 2013-04-11 | 2013-04-11 | Laminitis treatment system and method |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2983634A1 true EP2983634A1 (de) | 2016-02-17 |
EP2983634A4 EP2983634A4 (de) | 2017-04-19 |
EP2983634B1 EP2983634B1 (de) | 2020-07-01 |
Family
ID=51689882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13881978.4A Active EP2983634B1 (de) | 2013-04-11 | 2013-04-11 | System und verfahren zur behandlung von hufrehe |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2983634B1 (de) |
WO (1) | WO2014168624A1 (de) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5014681A (en) * | 1989-05-05 | 1991-05-14 | Mego Afek Industrial Measuring Instruments | Method and apparatus for applying intermittent compression to a body part |
US5167227A (en) * | 1991-08-15 | 1992-12-01 | Meserlian Sarkis B | Apparatus for massaging and/or controllably supporting the legs of a horse |
US5174382A (en) * | 1991-11-07 | 1992-12-29 | Wright Christopher A | Horses hoof cover with pump and method of use |
US20120203144A1 (en) * | 2011-02-07 | 2012-08-09 | Kci Licensing, Inc. | Methods and systems for treating a hoof on an ungulate mammal |
-
2013
- 2013-04-11 WO PCT/US2013/036179 patent/WO2014168624A1/en active Application Filing
- 2013-04-11 EP EP13881978.4A patent/EP2983634B1/de active Active
Non-Patent Citations (1)
Title |
---|
See references of WO2014168624A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP2983634B1 (de) | 2020-07-01 |
EP2983634A4 (de) | 2017-04-19 |
WO2014168624A1 (en) | 2014-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012216883B2 (en) | Improvements in or relating to footwear | |
JP4519125B2 (ja) | 四肢用圧迫装置 | |
US20240139061A1 (en) | Support device | |
US8465444B1 (en) | Laminitis treatment system and method | |
US6589194B1 (en) | Self-powered compression devices and methods for promoting circulation and therapeutic compression | |
US8226586B2 (en) | Negative pressure, compression therapy device | |
Wu et al. | The pivotal role of offloading in the management of neuropathic foot ulceration | |
US8454542B2 (en) | Positive pressure chamber for extremities | |
JP2017517375A5 (de) | ||
CN206896454U (zh) | 一种治疗下肢静脉曲张专用袜 | |
EP2983634B1 (de) | System und verfahren zur behandlung von hufrehe | |
WO2017134429A1 (en) | Support device | |
WO2011070567A1 (en) | Pneumatic therapeutic system for stimulating blood circulation | |
US20240164346A1 (en) | Equine Biomechanical Orthotic Device and Method of Use | |
US11998509B2 (en) | Support device | |
WO2023012830A1 (en) | A shoe insole to heal diabetic foot ulcers and method of manufacture thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20151109 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20170322 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61H 9/00 20060101AFI20170316BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20180308 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200117 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1285459 Country of ref document: AT Kind code of ref document: T Effective date: 20200715 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602013070409 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201001 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20200701 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1285459 Country of ref document: AT Kind code of ref document: T Effective date: 20200701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201102 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201002 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201001 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602013070409 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 |
|
26N | No opposition filed |
Effective date: 20210406 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602013070409 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210411 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210430 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210430 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211103 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20130411 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20230427 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230525 Year of fee payment: 11 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200701 |